Account
Insider Insights
06.04.2022
Cancer report recommends access to new treatments

The report looks at how differences in cancer survival rates between the UK and other countries have...

Read more
Insider Insights
05.04.2022
IPCEI to promote development of gene and cell ther

The IPCEI was signed to address the need to equip Europe with a strong, innovative and export-friend...

Read more
Insider Insights
25.03.2022
UK-wide commitments for genomics initiatives

According to the Department of Health and Social Care (DHSC), the commitments will enable patients t...

Read more
Insider Insights
24.03.2022
Manufacturer paybacks of E1 billion in relation to

Consequently, paybacks from pharmaceutical manufacturers of around €1 billion will be due from pha...

Read more
Insider Insights
24.03.2022
“First of its kind” MAA leads to NICE approval

The draft final guidance reverses previous guidance issued in November 2021 rejecting the drug for r...

Read more
Insider Insights
21.03.2022
Early access agreement

Patients in England will be the first in Europe to have access to Takeda’s Exkivity (mobocertinib)...

Read more
Insider Insights
21.03.2022
PRIME scheme has positive impact on the authorisat

PRIME medicines include CAR T-cell therapies, one-time potentially curative gene therapies, rare can...

Read more
Insider Insights
21.03.2022
Revise payment percentage paid

The DHSC is proposing to increase the statutory scheme payment percentage for 2022 from 10.9% to 14....

Read more
Insider Insights
17.03.2022
Germany: Proposed new pharmaceutical cost

The proposals are set out in the draft Statutory Health Insurance Financial Stabilisation Bill which...

Read more
Insider Insights
16.03.2022
Offering a price lower

Based on a recent decision by the Interministerial Commission on Medicines Prices offering a price l...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.